Use App
Trending
News
Earnings
All
DIA
1.93%
SPY
1.68%
QQQ
3.18%
Trending
ADBE
11.35%
MSFT
1.60%
RKLB
12.99%
USO
4.15%
SPACZZX
0.60%
SATS
12.63%
RDW
20.78%
NASA
15.36%
DXYZ
8.54%
RH
8.28%
ADBE
11.35%
MSFT
1.60%
RKLB
12.99%
USO
4.15%
SPACZZX
0.60%
SATS
12.63%
RDW
20.78%
NASA
15.36%
DXYZ
8.54%
RH
8.28%
home
Symbol
AZN
news
AZN
AstraZeneca PLC
$182.28
$3.32
(1.85%)
Today
·
Closed $182.28
$0.00
(0.00%)
After Hours
Updated:
04:15 PM EDT
1
8
,
8
2
2
1
8
,
8
2
2
Reported Earnings
Apr 29
Mkt Cap
$277.54B
Vol
1.67M
Full Chart
Fundamentals
Mkt Cap
$277.54B
Volume
-
52W High
$212.71
52W Low
$137.23
PE Ratio
26.70
Avg. Volume
1.8M
EPS (Annual)
$6.60
P/B
5.86
Rev/Employee
$611,227.89
Earnings
Apr 29
60
Bullish Sentiment
How do you feel about AZN?
Bullish
Bearish
Feed
News
Sentiment
Earnings
Fundamentals
Info
News
all
press releases
Can Linzess Continue Driving IRWD's Revenue Growth Through 2026?
Ironwood sees Linzess momentum as strong demand, a pediatric expansion and pricing changes are expected to boost revenues and profit in 2026.
Zacks
Share to Feed
More News
Merck Stock Moves Above 50-Day SMA: Assessing Its Investment Case
MRK has reclaimed its 50-day SMA while holding above its 200-day trendline, backed by Keytruda growth, pipeline advances and recent deals.
Zacks
AstraZeneca's GLP-1 Pill Heads To Late-Stage Trials
AstraZeneca advances oral GLP-1 elecoglipron to Phase 3 following strong weight loss & diabetes data at ADA 2026. Get the trial details.read more...
Benzinga
AstraZeneca's GLP-1 Pill Heads To Late-Stage Trials
AstraZeneca advances oral GLP-1 elecoglipron to Phase 3 following strong weight loss & diabetes data at ADA 2026. Get the trial details.read more...
Benzinga
JNJ and AZN Face Patent Headwinds: Which Stock Looks Stronger Now?
J&J's diversified healthcare business and growth outlook help it stand out against AstraZeneca despite patent and legal challenges.
Zacks
LLY Stock Climbs As Oral GLP-1 Pill Beats Novo Nordisk, AstraZeneca’s Therapies In Diabetes Trials
Lilly’s Foundayo outperformed existing treatments on blood sugar control and weight loss in type 2 diabetes patients in three late-stage trials.
Stocktwits
Full Article
AstraZeneca Reports Significant Proteinuria Reduction With Ultomiris In Rare Kidney Disease
AstraZeneca's Ultomiris cut proteinuria by 46.6% in Phase 3 IgAN trial interim analysis, supporting regulatory filings.read more...
Benzinga
AstraZeneca Reports Significant Proteinuria Reduction With Ultomiris In Rare Kidney Disease
AstraZeneca's Ultomiris cut proteinuria by 46.6% in Phase 3 IgAN trial interim analysis, supporting regulatory filings.read more...
Benzinga
Should You Buy, Sell or Hold ABBV Stock After It Rises 12% in a Month?
ABBV climbs 12% a month as investors weigh the raised 2026 guidance, Skyrizi and Rinvoq growth, and multiple pipeline updates.
Zacks
FDA Milestones Fueling Expansion
The biotechnology sector delivered several notable developments. $TNGX, $NTHI, $AIM, $AZN, $NRIX, $NYXH
24-7 Market News
<
1
2
...
>
Advertisement
|
Remove ads.
Latest AZN News
View
Can Linzess Continue Driving IRWD's Revenue Growth Through 2026?
Zacks
Merck Stock Moves Above 50-Day SMA: Assessing Its Investment Case
Zacks
AstraZeneca's GLP-1 Pill Heads To Late-Stage Trials
Benzinga
Loading...
Advertisement
|
Remove ads.
Advertisement
|
Remove ads.
Watchlist
Trending
News
Explore
Community
Profile